Advances in the management of patients with non-Hodgkin's lymphoma

Jack M. Lionberger, James Olen Armitage

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Non-Hodgkin's lymphoma is the fifth most common cause of death due to cancer and has been rising at a rate of 4% per year for the last four decades. Although 'traditional' chemotherapy and radiotherapy have had important contributions to improving outcomes, new tools in the treatment of non-Hodgkin's lymphoma are needed. This review describes therapeutic modalities that are currently being used or are in the process of being developed and which are based on concepts divergent from 'traditional' approaches to managing non-Hodgkin's lymphoma.

Original languageEnglish (US)
Pages (from-to)43-52
Number of pages10
JournalExpert review of anticancer therapy
Volume1
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

Non-Hodgkin's Lymphoma
Cause of Death
Radiotherapy
Drug Therapy
Therapeutics
Neoplasms

Keywords

  • Allogeneic
  • Antibiotic
  • Antisense
  • Autologous
  • Lymphoma
  • Monoclonal
  • Transplantation
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Advances in the management of patients with non-Hodgkin's lymphoma. / Lionberger, Jack M.; Armitage, James Olen.

In: Expert review of anticancer therapy, Vol. 1, No. 1, 01.01.2001, p. 43-52.

Research output: Contribution to journalReview article

@article{f8a692aaa86446698905b5964a8e8963,
title = "Advances in the management of patients with non-Hodgkin's lymphoma",
abstract = "Non-Hodgkin's lymphoma is the fifth most common cause of death due to cancer and has been rising at a rate of 4{\%} per year for the last four decades. Although 'traditional' chemotherapy and radiotherapy have had important contributions to improving outcomes, new tools in the treatment of non-Hodgkin's lymphoma are needed. This review describes therapeutic modalities that are currently being used or are in the process of being developed and which are based on concepts divergent from 'traditional' approaches to managing non-Hodgkin's lymphoma.",
keywords = "Allogeneic, Antibiotic, Antisense, Autologous, Lymphoma, Monoclonal, Transplantation, Vaccine",
author = "Lionberger, {Jack M.} and Armitage, {James Olen}",
year = "2001",
month = "1",
day = "1",
doi = "10.1586/14737140.1.1.43",
language = "English (US)",
volume = "1",
pages = "43--52",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Advances in the management of patients with non-Hodgkin's lymphoma

AU - Lionberger, Jack M.

AU - Armitage, James Olen

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Non-Hodgkin's lymphoma is the fifth most common cause of death due to cancer and has been rising at a rate of 4% per year for the last four decades. Although 'traditional' chemotherapy and radiotherapy have had important contributions to improving outcomes, new tools in the treatment of non-Hodgkin's lymphoma are needed. This review describes therapeutic modalities that are currently being used or are in the process of being developed and which are based on concepts divergent from 'traditional' approaches to managing non-Hodgkin's lymphoma.

AB - Non-Hodgkin's lymphoma is the fifth most common cause of death due to cancer and has been rising at a rate of 4% per year for the last four decades. Although 'traditional' chemotherapy and radiotherapy have had important contributions to improving outcomes, new tools in the treatment of non-Hodgkin's lymphoma are needed. This review describes therapeutic modalities that are currently being used or are in the process of being developed and which are based on concepts divergent from 'traditional' approaches to managing non-Hodgkin's lymphoma.

KW - Allogeneic

KW - Antibiotic

KW - Antisense

KW - Autologous

KW - Lymphoma

KW - Monoclonal

KW - Transplantation

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0035557912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035557912&partnerID=8YFLogxK

U2 - 10.1586/14737140.1.1.43

DO - 10.1586/14737140.1.1.43

M3 - Review article

C2 - 12113132

AN - SCOPUS:0035557912

VL - 1

SP - 43

EP - 52

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -